{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:26:55Z","timestamp":1789349215502,"version":"build-2803163510"},"reference-count":35,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1253\/circj.cj-12-1573","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T01:28:19Z","timestamp":1382405299000},"page":"194-205","source":"Crossref","is-referenced-by-count":28,"title":["Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis"],"prefix":"10.1253","volume":"78","author":[{"given":"Atsushi","family":"Hirayama","sequence":"first","affiliation":[{"name":"Division of Cardiology, Nihon University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Tanahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, International Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Chachin","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Japan Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Sugioka","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"on behalf of all ACCEPT study investigators in Japan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":" 1. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 455–474.","DOI":"10.1002\/acr.21596"},{"key":"2","doi-asserted-by":"crossref","unstructured":" 2. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–1155.","DOI":"10.1136\/ard.2003.011742"},{"key":"3","unstructured":" 3. National Institute for Health and Clinical Excellence. Osteoarthritis: The care and management of osteoarthritis in adults. NICE clinical guideline 59. Available at: http:\/\/www.nice.org.uk\/nicemedia\/live\/11926\/39557\/39557.pdf (accessed March 15, 2012)."},{"key":"4","unstructured":" 4. National Institute for Health and Clinical Excellence. Rhematoid arthritis: The management of rheumatoid arthritis in adults. NICE clinical guideline 79. Available at: http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG79NICEGuideline.pdf (accessed March 15, 2012)."},{"key":"5","doi-asserted-by":"crossref","unstructured":" 5. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669–681.","DOI":"10.1136\/ard.2004.028886"},{"key":"6","doi-asserted-by":"crossref","unstructured":" 6. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999; 74: 1095–1105.","DOI":"10.4065\/74.11.1095"},{"key":"7","doi-asserted-by":"crossref","unstructured":" 7. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002; 325: 619.","DOI":"10.1136\/bmj.325.7365.619"},{"key":"8","doi-asserted-by":"crossref","unstructured":" 8. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999; 354: 2106–2111.","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":" 9. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001; 29: 467–479.","DOI":"10.1177\/147323000102900602"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30: 11–18.","DOI":"10.1080\/030097401750065265"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999; 282: 1921–1928.","DOI":"10.1001\/jama.282.20.1921"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119: 255–266.","DOI":"10.1016\/j.amjmed.2005.09.054"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633–1644.","DOI":"10.1001\/jama.296.13.jrv60011"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098, doi:0.1371\/journal.pmed.1001098.","DOI":"10.1371\/journal.pmed.1001098"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59: 1097–1104.","DOI":"10.1002\/art.23911"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–1255.","DOI":"10.1001\/jama.284.10.1247"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–1080.","DOI":"10.1056\/NEJMoa050405"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885–895.","DOI":"10.1056\/NEJMoa061652"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, et al. Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99: 91–98.","DOI":"10.1016\/j.amjcard.2006.07.069"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J R Soc Med 2006; 99: 132–140.","DOI":"10.1177\/014107680609900315"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kawahito Y. Clinical implications of cyclooxygenase-2 inhibitors. Inflamm Regen 2007; 27: 552–558.","DOI":"10.2492\/inflammregen.27.552"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17: 200–208.","DOI":"10.1002\/pds.1471"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: The Hisayama study. Stroke 2003; 34: 2349–2354.","DOI":"10.1161\/01.STR.0000090348.52943.A2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, et al. Ten year recurrence after first ever stroke in a Japanese community: The Hisayama study. J Neurol Neurosurg Psychiatry 2005; 76: 368–372.","DOI":"10.1136\/jnnp.2004.038166"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906–2913.","DOI":"10.1161\/CIRCULATIONAHA.106.616219"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950–1957.","DOI":"10.1161\/CIRCULATIONAHA.105.602425"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation 2008; 117: 2104–2113.","DOI":"10.1161\/CIRCULATIONAHA.108.764530"},{"key":"28","unstructured":"28. ClinicalTrials.gov. Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen or Naproxen (PRECISION). NCT00346216. U.S.National Institutes of Health. Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00346216 (accessed August 29, 2012)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173–1181.","DOI":"10.1016\/S0140-6736(09)62100-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Miyauchi K, Yamazaki T, Watada H, Tanaka Y, Kawamori R, Imai Y, et al. Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes. Circ J 2012; 76: 2159–2166.","DOI":"10.1253\/circj.CJ-11-1406"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ueshima K, Oba K, Yasuno S, Fujimoto A, Tanaka S, Ogihara T, et al. Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients: Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Circ J 2011; 75: 2411–2416.","DOI":"10.1253\/circj.CJ-10-1161"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nakagomi A, Kodani E, Takano H, Uchida T, Sato N, Ibuki C, et al. Secondary preventive effects of a calcium antagonist for ischemic heart attack: Randomized parallel comparison with β-blockers. Circ J 2011; 75: 1696–1705.","DOI":"10.1253\/circj.CJ-10-1078"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Uemura S, et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure: Subanalysis from the JPAD trial. Circ J 2012; 76: 1526–1532.","DOI":"10.1253\/circj.CJ-11-1033"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: A placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther 2013; 37: 346–354.","DOI":"10.1111\/apt.12174"},{"key":"35","unstructured":"35. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: Quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29: 1015–1022."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/78\/1\/78_CJ-12-1573\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T04:08:38Z","timestamp":1616645318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/78\/1\/78_CJ-12-1573\/_article"}},"subtitle":["\u2013 A 3-Year Nationwide Comparative Observational Study in Japan (ACCEPT) \u2013"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-12-1573","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}